Spyre Therapeutics Inc (SYRE)

EBITDA Growth

30.30%

Quarterly · Period ending:

SYRE logo

SYRE EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported30.30%
SYRE Quarterly EBITDA YoY % (-186.45% → 30.30%)
High-resolution chart · PNG

SYRE ebitda growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Spyre Therapeutics Inc EBITDA Growth — Quarterly
Period endingEBITDA Growth
30.2975%
-68.8868%
-11.0756%
83.7951%
-33.7256%
-2.1974%
-17.8854%
-107.5863%
-37.0202%
-144.6957%
-159.5467%
-85.2962%
-29.7862%
25.4775%
8.0602%
9.7036%
-244.4637%
-34.6085%
10.6886%
-11.1739%
70.2877%
5.3742%
-2.7703%
18.9147%
-15.2471%
-7.4671%
-43.13%
-81.1539%
-92.9651%
-114.7645%
-132.2104%
-53.4494%
-44.1123%
-30.1959%
-19.1211%
-26.5199%
-21.8967%
-38.3649%
-38.7853%
-84.7583%
-286.2801%
-85.0734%
-25.213%
-8.1978%
18.029%
-186.4486%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.